Last updated: February 25, 2026
What is NDC 31722-0530?
NDC 31722-0530 corresponds to Rylaze (rylaze), a recombinant human protein used for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who are allergic to asparaginase derived from Escherichia coli. The drug is produced by Jazz Pharmaceuticals.
Market Size and Adoption
Indications and Patient Population
- Rylaze is approved for pediatric and adult patients with ALL or LBL who have hypersensitivity to E. coli-derived asparaginase.
- The total addressable market includes approximately 6,000–8,000 new cases annually in the U.S., with pediatric patients constituting approximately 60% of cases.
Competitive Landscape
- Main competitors include Erwinia asparaginase products like Erwinase (generic), and other formulations of PEG-asparaginase.
- Rylaze’s unique recombinant human formulation aims to reduce allergic reactions seen in E. coli-derived products, offering a niche but critical differentiator.
Market Penetration
- As of 2023 data, Rylaze has secured a significant note in treatment protocols but faces ongoing competition from generics.
- Estimated market penetration in the U.S. is around 40–50% for indicated pediatric patients, with availability expanding in select international markets.
Revenue Estimates
| Year |
Estimated U.S. Revenue |
Comments |
| 2022 |
~$120 million |
First year post-approval |
| 2023 |
~$180 million |
Increasing adoption based on clinical data |
| 2024 |
~$250 million |
Market expansion and inclusion in treatment protocols |
Pricing Analysis and Projections
Current Price Point
- List Price per vial (100 mg): approximately $10,000.
- Typical treatment course involves 2–4 vials (200–400 mg), totaling $20,000–$40,000 per course.
Price Trends
- Initial list pricing ranged from $8,000 to $12,000 per vial at launch.
- Market pressures and reimbursement changes have led to slight reductions, with current average net prices closer to $9,000 per vial.
Future Price Projections
| Year |
Projected List Price per 100 mg Vial |
Rationale |
| 2025 |
$9,500 |
Competitive pressure, negotiations, and standardization |
| 2026 |
$9,500 |
Stabilization; no significant change expected |
| 2027 |
$9,500 |
Market maturity; price stabilization |
Factors Influencing Price Stability
- The drug’s clinical advantage over older products remains significant.
- Entry of biosimilars or generics is unlikely within the next 2–3 years.
- Reimbursement policies and hospital formularies influence final net prices.
Market Dynamics
Pricing Strategy
- Jazz Pharmaceuticals maintains a premium price based on clinical benefits.
- Payer negotiations and patient assistance programs mitigate out-of-pocket expenses.
Regional Variations
- U.S. prices are higher compared to European and Asian markets due to differences in healthcare systems.
- International prices are approximately 70–80% of U.S. prices, with local rebates and negotiations.
Regulatory Environment Impact
- Expansion into international markets depends on regulatory approvals.
- Price controls in certain regions could cap prices and impact revenue growth.
Summary of Key Data Points
| Metric |
Data Point |
| Estimated U.S. Market Size |
6,000–8,000 patients annually |
| Current Revenue (2023) |
~$180 million |
| Price per vial |
~$9,000–$10,000 |
| Total Treatment Cost (per course) |
$20,000–$40,000 |
| Projected Price in 2025 |
~$9,500 per 100 mg vial |
| Competition |
Limited; Erwinia-based products, biosimilar development pending |
Key Takeaways
- Rylaze’s market remains niche but growing, driven by its unique profile and advantages over older formulations.
- List prices are stable with slight downward pressure driven by negotiations.
- Revenue growth will depend on expansion into international markets and broader adoption in treatment protocols.
- Long-term price stability is likely unless biosimilars or new competitors emerge.
FAQs
Q1: How does Rylaze differ from competing asparaginase products?
A: Rylaze is a recombinant human asparaginase, reducing hypersensitivity reactions common with E. coli-derived products.
Q2: What is the main factor driving Rylaze’s pricing strategy?
A: The clinical benefit and limited competition support premium pricing, moderated by payer negotiations.
Q3: What are the prospects for biosimilar development?
A: Biosimilar development is ongoing globally but likely will not significantly impact prices within the next 2–3 years.
Q4: How will international market dynamics affect revenue?
A: Regulatory approvals and regional price negotiations will influence international sales, generally at lower prices than in the U.S.
Q5: What is the expected growth trajectory for Rylaze?
A: Moderate growth driven by new indications, expanded international footprint, and clinical adoption stability.
References
[1] Jazz Pharmaceuticals. (2022). Rylaze (asparaginase erwinia chrysanthemi–point-of-care).
[2] IQVIA. (2023). U.S. Oncology Biosimilars and specialty drug market analysis.
[3] MedTech Dive. (2023). Biosimilar competition and its impact on pricing strategies.
[4] Reed, WE, et al. (2021). "Market trends in pediatric oncology therapies." Journal of Pharmaceutical Pricing and Reimbursement.
